i
Important informations
Instagram
Portal
Donate now

Our researchers

Aucun résultat

Antonis Koromilas

Antonis E. Koromilas, PhD

Cancer

Apoptosis, Cell cycle control, Cell proliferation, Endoplasmic-reticulum stress, Interferon, mRNA translation, Protein phosphorylation, Signal transduction, Tumor suppressor p53, Virus infection, Virus-mediated oncogenesis
  • Senior Investigator, Lady Davis Institute for Medical Research
  • Professor, Gerald Bronfman Department of Oncology, McGill University
  • Associate Member, Goodman Cancer Research Center, McGill University
  • Associate Member, Department of Microbiology and Immunology, McGill University

Contact details

(514) 340-8222 ext. 23697
antonis.koromilas@mcgill.ca

Snapshot

We study how oncogenic forms of stress influence tumor development and their responses to chemotherapy. Our research focuses on the integrated stress response (ISR), a key pathway that determines the efficacy of adaptation processes through the regulation of protein synthesis. We examine the anti-tumor efficacy of drugs targeting protein synthesis pathways and how tumor cells adapt to these treatments. Additionally, we investigate the function of the transcription factor STAT1 in solid cancers to understand its pro-survival mechanisms and their impact on cancer therapies.

The long-term goals of our research are to:

  • Investigate the function of ISR in tumor evolution via tumor intrinsic and immune regulatory mechanisms.
  • Explore the therapeutic significance of targeting ISR for cancer treatment.
  • Determine the anti-tumor efficacy of drugs targeting protein synthesis pathways.
  • Elucidate the cytoprotective effects of STAT1 in anti-cancer treatment.

Important Links :

See Antonis E. Koromilas' publications on PubMed

Major Research Activities

  • We investigate the effects of ISR in tumor evolution by activating the KRAS oncogene in lung cells. We identify genes influenced by ISR at the translational level and characterize pathways involved in tumor development and responses to chemotherapeutic drugs.
  • We explore the role of tumoral ISR in regulating immune responses that influence lung cancer progression. We investigate the mechanisms utilized by ISR to recruit immune cells into the tumor bed and determine their function in tumor progression and efficacy in anti-tumor treatments.
  • We determine the anti-tumor effects of protein synthesis inhibitors the treatment of breast cancers. We also explore tumor-specific targeting approaches to improve breast cancer treatment.
  • We analyze the tumorigenic and pro-survival effects of STAT1 in mutant KRAS cancers. We identify STAT1-depenedent pathways implicated in the resistance of tumor cells to chemotherapeutic drugs targeting oncogenic and metabolic pathways.

Recent Publications and References